TanguyYannLim-SeiwertMDTanguy Seiwert, MD

Oncology • Baltimore, MD

Head & Neck Cancer, Thoracic Cancer

Johns Hopkins University

Join to view full profile

Dr. Lim-Seiwert is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Lim-Seiwert's full profile

Already have an account?

Office
201 North Broadway, Viragh 8156, Box 6
Johns Hopkins University
Baltimore, MD 21287
Is this information wrong?

Summary

Dr. Tanguy Seiwert is an oncologist in Baltimore, MD. He received his medical degree from Johannes Gutenberg University of Mainz Faculty of Medicine and has been in practice 18 years. He specializes in head & neck cancer and thoracic cancer.

Education & Training

Johannes Gutenberg University of Mainz Faculty of MedicineClass of 1999

Certifications & Licensure

MD State Medical License 2019 - 2024
IL State Medical License 2003 - 2020
American Board of Internal Medicine Medical Oncology

Clinical Trials

Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Start of enrollment: 2010 Nov 01
Completed
Phase 2
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2012 Nov 12
Terminated
Phase 1, Phase 2
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery Start of enrollment: 2012 Aug 20
Completed
Phase 2
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Start of enrollment: 2013 May 01
Completed
Phase 1, Phase 2
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer Start of enrollment: 2018 Jun 01
Terminated
Phase 2
A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study Start of enrollment: 2017 May 10
Active, not recruiting
Phase 2
Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer Start of enrollment: 2017 Jun 27
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Institution's Experience.
Raymond J So, Henry H Joo, Emily Y Huang, Christopher Rayle, Tanguy Y Seiwert, Eric H Raabe, Simon R Best> ;The Laryngoscope. 2024 Mar 25
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
Tanguy Y Seiwert, Sophie Wildsmith, Jérôme Fayette, Kevin Harrington, Maura Gillison, Myung-Ju Ahn, Shunji Takahashi, Jared Weiss, Jean-Pascal Machiels, Shrujal Baxi, ...> ;Cancer Immunology, Immunotherapy. 2024 Mar 2
Neoadjuvant chemotherapy for advanced oral cavity cancer.
Yaniv, D., Barbon, C., Smith, J., Gross, N., Seiwert, T., Margalit, D., Williams, M., Largo, R.> ;CA. 2024 Feb 8
Neoadjuvant immunotherapy is safe before surgery in head and neck squamous cell carcinoma. Is it time to challenge the standard-of-care?
Gross, N., Seiwert, T.> ;Cancer. 2024 Mar 15
Allergy History and Immunotherapy Response in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Alkhatib, H., Hosam H Alkhatib, Christopher A Maroun, Meytal Guller, Dylan J Cooper, Evan S Wu, David W Eisele, Carole Fakhry, Drew Pardoll, Tanguy Y Seiwert, Gangcai ...> ;Otolaryngology--Head and Neck Surgery. 2024 Mar 1
Impact of comorbidities on outcomes in patients with advanced head and neck cancer undergoing immunotherapy.
Alkhatib, H., Meytal Guller, Dylan J Cooper, Hosam Alkhatib, Aditya Suru, Angelo Blancaflor, Christopher A Maroun, Tristan Tham, Hailey Allen, Eden Mazzara, Jerin Thom...> ;Head & Neck. 2023 Nov 1
3 citations
Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement.
Raymond J So, Julio C Hidalgo Lopez, Samir A Ballestas, Adam M Klein, Conor Steuer, Dong M Shin, Marin Abousaud, Yong Teng, Nabil F Saba, Andrew T Tkaczuk, Eric S Scha...> ;The Laryngoscope. 2024 Feb 1
1 citations
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
A J Rosenberg, C-Y Liao, T Karrison, J A de Souza, F P Worden, B Libao, M K Krzyzanowska, D N Hayes, E Winquist, V Saloura, K Prescott, V M Villaflor, T Y Seiwert, R B...> ;Annals of Oncology. 2023 Aug 1
3 citations
Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma.
Jacob J Adashek, Surendra Sapkota, Rodrigo de Castro Luna, Tanguy Y Seiwert> ;NPJ Precision Oncology. 2023 Apr 11
6 citations
The role of macrophages in the tumor microenvironment and tumor metabolism.
Pritam Sadhukhan, Tanguy Y Seiwert> ;Seminars in Immunopathology. 2023 Mar 1
33 citations
Persistent mutation burden drives sustained anti-tumor immune responses.
Noushin Niknafs, Archana Balan, Christopher Cherry, Karlijn Hummelink, Kim Monkhorst, Xiaoshan M Shao, Zineb Belcaid, Kristen A Marrone, Joseph Murray, Kellie N Smith,...> ;Nature Medicine. 2023 Feb 1
27 citations
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KE...
A Psyrri, J Fayette, K Harrington, M Gillison, M-J Ahn, S Takahashi, J Weiss, J-P Machiels, S Baxi, A Vasilyev, A Karpenko, M Dvorkin, C-Y Hsieh, S C Thungappa, P P Se...> ;Annals of Oncology. 2023 Mar 1
6 citations
Clinical Uncertainties of Circulating Tumor DNA in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma in the Absence of National Comprehensive Cancer N...
Deborah X Xie, Carmen Kut, Harry Quon, Tanguy Y Seiwert, Gypsyamber D'Souza, Carole Fakhry> ;Journal of Clinical Oncology. 2023 May 10
8 citations
Biomarkers predictive of response to pembrolizumab in head and neck cancer.
David G Pfister, Robert I Haddad, Francis P Worden, Jared Weiss, Ranee Mehra, Laura Q M Chow, Stephen V Liu, Hyunseok Kang, Nabil F Saba, Lori J Wirth, Ammar Sukari, E...> ;Cancer Medicine. 2023 Mar 1
5 citations
Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Charu Aggarwal, Nabil F Saba, Alain Algazi, Ammar Sukari, Tanguy Y Seiwert, Missak Haigentz, Mercedes Porosnicu, Marcelo Bonomi, Jean Boyer, Mark T Esser, Lily I Cheng...> ;Clinical Cancer Research. 2023 Feb 1
32 citations
Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug.
Rana Rais, Kathryn M Lemberg, Lukáš Tenora, Matthew L Arwood, Arindom Pal, Jesse Alt, Ying Wu, Jenny Lam, Joanna Marie H Aguilar, Liang Zhao, Diane E Peters, Carolyn T...> ;Science Advances. 2022 Nov 18
4 citations
A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck.
Cherie-Ann O Nathan, D Neil Hayes, Theodore Karrison, Olivier Harismendy, José M Flores, Tara Moore-Medlin, Everett E Vokes, J Silvio Gutkind, Prakash Neupane, Glenn M...> ;Clinical Cancer Research. 2022 Dec 1
Spontaneous regression of an human papillomavirus-positive oropharyngeal squamous cell carcinoma.
Stefanie Seo, Lisa Rooper, Tanguy Y Seiwert, Carole Fakhry> ;Head & Neck. 2023 Jan 1
2 citations
Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamou...
Ari J Rosenberg, Nishant Agrawal, Alexander T Pearson, Zhen Gooi, Elizabeth Blair, Louis Portugal, John F Cursio, Aditya Juloori, Jeffrey Chin, Kathryn Rouse, Victoria...> ;British Journal of Cancer. 2022 Nov 1
2 citations
Interrogation of T Cell-Enriched Tumors Reveals Prognostic and Immunotherapeutic Implications of Polyamine Metabolism.
R Alex Harbison, Rajeev Pandey, Michael Considine, Robert D Leone, Tracy Murray-Stewart, Rossin Erbe, Raj Mandal, Mark Burns, Robert A Casero Jr, Tanguy Seiwert, Carol...> ;Cancer Research Communications. 2022 Jul 1
Reply to "Guarantee-time bias in studies on the relationship between immune-related adverse events and antitumor activity".
Corey C Foster, Tanguy Y Seiwert> ;Cancer. 2022 Jul 1
1 citations
Tumor Histological Grade and Immunotherapy Response in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Hosam H Alkhatib, Christopher A Maroun, Neha Amin, Gangcai Zhu, Meytal Guller, Matthew E Herberg, Evan S Wu, Tanguy Y Seiwert, Lisa M Rooper, David W Eisele, Carole Fa...> ;JAMA Otolaryngology-- Head & Neck Surgery. 2022 Jun 1
28 citations
Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy.
Michael Hwang, Jenna Vanliere Canzoniero, Samuel Rosner, Guangfan Zhang, James R White, Zineb Belcaid, Christopher Cherry, Archana Balan, Gavin Pereira, Alexandria Cur...> ;Journal for Immunotherapy of Cancer. 2022 Jun 1
15 citations
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
Timothy A Yap, Justin F Gainor, Margaret K Callahan, Gerald S Falchook, Russell K Pachynski, Patricia LoRusso, Shivaani Kummar, Geoffrey T Gibney, Howard A Burris, Sco...> ;Clinical Cancer Research. 2022 Sep 1
15 citations
Comparison of next generation sequencing, droplet digital PCR, and quantitative real-time PCR for the earlier detection and quantification of HPV in HPV-positive oroph...
Austin K Mattox, Gypsyamber D'Souza, Zubair Khan, Hailey Allen, Stephanie Henson, Tanguy Y Seiwert, Wayne Koch, Drew M Pardoll, Carole Fakhry> ;Oral Oncology. 2022 May 1
Join now to see all

Press Mentions

Reduced RT Feasible in Chemo-Sensitive HPV-Associated Head and Neck CancerFebruary 19th, 2018
Lower-Dose Radiation Therapy Effective and Safe for HPV-Related Head and Neck Cancer After Induction Chemotherapy, Trial FindsFebruary 13th, 2018
Future of Immunotherapy in Head and Neck Cancer May Be in CombinationsMay 22nd, 2017
Join now to see all